Kidney amyloidosis is one of the most serious potential complication of chronic inflammatory disorders, including rheumatoid arthritis. Interleukin-6 blockade is frequently effective in rheumatic disease, however, there are only few published data on its use in AA amyloidosis. Here, we report a case of patient with rheumatoid arthritis complicated by nephrotic syndrome due to secondary type A amyloidosis successfully treated with tocilizumab. Renal amyloidosis secondary to rheumatoid arthritis effectively treated with tocilizumab
INtROduCtION
Amyloidosis is a heterogeneous group of diseases in which insoluble protein fibres with an abnormal structure and resistant to proteolysis build up in the extracellular space [1] . Localised or systemic forms of the disease are distinguished depending on whether deposits build up in one or in many organs [1] . The kidneys are among the most affected organs [2] .
Amyloidosis is classified on the basis of the type of protein precursor that makes the majority of deposits. The names of amyloidosis variations start with the letter "A" and include other letters, which refer to the type of abnormal protein [3] . Traditionally, amyloidosis is divided into primary and secondary. Primary amyloidosis (AL) is associated with monoclonal gammopathy and other types of leukaemia [1] . Secondary amyloidosis (AA) is secondary to chronic inflammatory diseases in the majority of cases [4] .
Nowadays, amyloidosis is primarily caused by non-infectious inflammatory diseases. It is most common in rheumatoid arthritis (RA) and constitutes 5-20% of complications of rheumatic diseases. The kidneys are among the most affected organs [4, 5] .
Renal amyloidosis is a consequence of a chronic inflammatory process that involves the deposition of insoluble AA protein in the glomeruli. Acute-phase SAA protein is the precursor of the A amyloid. It is produced in the liver and transported by high--density lipoproteins [5] . The most common first symptom of kidney involvement in renal amyloidosis includes nephrotic range proteinuria and progressive kidney failure. Kidney involvement may be accompanied by diarrhoea, malabsorption, and cardiomyopathy. The diagnosis of renal amyloidosis is confirmed by a histological examination of a kidney biopsy specimen [6] .
The treatment of this disease is difficult and closely related to the treatment of the underlying disease. The lower the activity of the underlying disease, the higher the chance of preventing the development of renal amyloidosis. Causal treatment involves reducing the production of protein precursors of amyloid fibrils (SAA) through limiting inflammation [7] . Therefore, appropriately selected classic disease-modifying antirheumatic drugs and the retention of a low activity of the disease may inhibit the development of amyloidosis. However, it is currently believed that biological drugs are first-choice drugs in the treatment of AA amyloidosis secondary to RA [6, 7] .
CASE Study
This paper presents a 57-year-old patient with secondary amyloidosis secondary to rheumatoid arthritis, in whom biological treatment (tocilizumab) was effective.
The patient has long-term and active rheumatoid arthritis, which was diagnosed in 2001. The treatment included methotrexate, sulfasalazine, and leflunomide one by one in standard recommended doses as well as periodically administered nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. However, disease remission was only partial.
In May 2014, nephrotic range proteinuria (up to 5 g/day) was diagnosed, while the excretory function of the kidneys was normal (glomerular filtration rate [eGFR] > 90 ml/min/1.73 m 2 ). In September 2014, renal amyloidosis was diagnosed based on the examination of a kidney biopsy specimen. As a result, the patient began to be treated with cyclophosphamide in November 2014 (800 mg i.v. acc. to the standard regiment; 4.0 g of the drug was administered in total). In spite of the treatment, treatment response was not significant (persistent nephrotic range proteinuria). In June 2015, the patient started to be treated with cyclosporin A (controlled via drug concentration in the serum), but no significant reduction of proteinuria was achieved.
Given the ineffectiveness of synthetic disease-modifying antirheumatic drugs, biological treatment with tocilizumab was initiated (in a dose of 8 mg/kg m.c. i.v., acc. to the standard regime 1 ×/4 weeks). At the start of the treatment, the disease activity in the patient was high: DAS-28 = 5.63, OB = 36 mm/h, proteinuria = 1.8 g/day. The tocilizumab treatment resulted in a partial remission of the underlying disease and a considerable reduction of proteinuria that is still present. After 18 months from the beginning of the treatment, the disease activity in the patient was as follows: DAS-28 < 3.2; OB < 20 mm/h; proteinuria < 0.3 g/day. Furthermore, the excretory function of the kidneys is still normal (eGFR > 90 ml/min/1.73 m 2 ).
dISCuSSION
Tocilizumab is a recombinant humanized monoclonal antibody of an immunoglobulin G1 (IgG1) subclass against interleukin-6 receptors: both soluble receptors (sIL-6R) and membrane receptors (mIL-6R). It has been proven that tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R [8] . It is effectively used to treat rheumatoid arthritis also in patients after an ineffective treatment with inhibitors of tumour necrosis factor a (TNF-a) [9] . In the literate, there are reports on the effectiveness of the IL-6 blockade in the case of amyloidosis secondary to rheumatic diseases, the prognosis of which has been very unfavourable so far [10] . The first description of the effectiveness of tocilizumab in treating secondary amyloidosis was published as early as in 2006 [11] . In the following years, it was proven that the use of tocilizumab to treat renal amyloidosis secondary to rheumatic diseases reduces proteinuria and allows the renal function to be normal for a longer time which, in turn, delays the necessity to begin renal replacement therapy [10, 12-14]. Therefore, it seems that tocilizumab is the drug of first choice for amyloidosis secondary to rheumatic diseases. czenie do rozwoju amyloidozy nerek. Leczenie przyczynowe obejmuje zmniejszenie wytwarzania białek prekursorowych włókien amyloidu (SAA), poprzez ograniczenie stanu zapalnego [7] . W związku z tym, odpowiednio dobrane klasyczne leki modyfikujące przebieg choroby i utrzymanie niskiej aktywności choroby mogą hamować rozwój amyloidozy. Jednak obecnie uważa się, że lekami z wyboru w leczeniu skrobiawicy AA w przebiegu RZS są leki biologiczne [6, 7] .
